» Articles » PMID: 27166196

Lysophosphatidic Acid Stimulates Epithelial to Mesenchymal Transition Marker Slug/Snail2 in Ovarian Cancer Cells Via Gαi2, Src, and HIF1α Signaling Nexus

Overview
Journal Oncotarget
Specialty Oncology
Date 2016 May 12
PMID 27166196
Citations 36
Authors
Affiliations
Soon will be listed here.
Abstract

Recent studies have identified a critical role for lysophosphatidic acid (LPA) in the progression of ovarian cancer. Using a transcription factor activation reporter array, which analyzes 45 distinct transcription factors, it has been observed that LPA observed robustly activates the transcription factor hypoxia-induced factor-1α (HIF1α) in SKOV3.ip ovarian cancer cells. HIF1α showed 150-fold increase in its activation profile compared to the untreated control. Validation of the array analysis indicated that LPA stimulates a rapid increase in the levels of HIF1α in ovarian cancer cells, with an observed maximum level of HIF1α-induction by 4 hours. Our report demonstrates that LPA stimulates the increase in HIF1α levels via Gαi2. Consistent with the role of HIF1α in epithelial to mesenchymal transition (EMT) of cancer cells, LPA stimulates EMT and associated invasive cell migration along with an increase in the expression levels N-cadherin and Slug/Snail2. Using the expression of Slug/Snail2 as a marker for EMT, we demonstrate that the inhibition of Gαi2, HIF1α or Src attenuates this response. In line with the established role of EMT in promoting invasive cell migration, our data demonstrates that the inhibition of HIF1α with the clinically used HIF1α inhibitor, PX-478, drastically attenuates LPA-stimulates invasive migration of SKOV3.ip cells. Thus, our present study demonstrates that LPA utilizes a Gαi2-mediated signaling pathway via Src kinase to stimulate an increase in HIF1α levels and downstream EMT-specific factors such as Slug, leading to invasive migration of ovarian cancer cells.

Citing Articles

Exploring the Role of Epithelial-Mesenchymal Transcriptional Factors Involved in Hematological Malignancy and Solid Tumors: A Systematic Review.

Kanwal R, Esposito J, Jawed B, Zakir S, Pulcini R, Martinotti R Cancers (Basel). 2025; 17(3).

PMID: 39941895 PMC: 11817253. DOI: 10.3390/cancers17030529.


Platelets as crucial players in the dynamic interplay of inflammation, immunity, and cancer: unveiling new strategies for cancer prevention.

Contursi A, Tacconelli S, Di Berardino S, De Michele A, Patrignani P Front Pharmacol. 2025; 15:1520488.

PMID: 39764464 PMC: 11701038. DOI: 10.3389/fphar.2024.1520488.


Downregulation of LPAR1 Promotes Invasive Behavior in Papillary Thyroid Carcinoma Cells.

Hosseini Z, Rajabi F, Morovatshoar R, Ashrafpour M, Behboodi P, Zareie D Cancer Inform. 2024; 23:11769351241277012.

PMID: 39253536 PMC: 11382228. DOI: 10.1177/11769351241277012.


Protein kinase D1 - A targetable mediator of pancreatic cancer development.

Fleming Martinez A, Storz P Biochim Biophys Acta Mol Cell Res. 2023; 1871(2):119646.

PMID: 38061566 PMC: 10872883. DOI: 10.1016/j.bbamcr.2023.119646.


Integration of an LPAR1 Antagonist into Liposomes Enhances Their Internalization and Tumor Accumulation in an Animal Model of Human Metastatic Breast Cancer.

Abdelmessih R, Xu J, Hung F, Auguste D Mol Pharm. 2023; 20(11):5500-5514.

PMID: 37844135 PMC: 10631474. DOI: 10.1021/acs.molpharmaceut.3c00348.


References
1.
De Craene B, Berx G . Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 2013; 13(2):97-110. DOI: 10.1038/nrc3447. View

2.
Mitra A, Davis D, Tomar S, Roy L, Gurler H, Xie J . In vivo tumor growth of high-grade serous ovarian cancer cell lines. Gynecol Oncol. 2015; 138(2):372-7. PMC: 4528621. DOI: 10.1016/j.ygyno.2015.05.040. View

3.
Imai T, Horiuchi A, Wang C, Oka K, Ohira S, Nikaido T . Hypoxia attenuates the expression of E-cadherin via up-regulation of SNAIL in ovarian carcinoma cells. Am J Pathol. 2003; 163(4):1437-47. PMC: 1868286. DOI: 10.1016/S0002-9440(10)63501-8. View

4.
Kumar R, Ha J, Radhakrishnan R, Dhanasekaran D . Transactivation of platelet-derived growth factor receptor alpha by the GTPase-deficient activated mutant of Galpha12. Mol Cell Biol. 2005; 26(1):50-62. PMC: 1317640. DOI: 10.1128/MCB.26.1.50-62.2006. View

5.
Seeber L, Horree N, Vooijs M, Heintz A, van der Wall E, Verheijen R . The role of hypoxia inducible factor-1alpha in gynecological cancer. Crit Rev Oncol Hematol. 2010; 78(3):173-84. DOI: 10.1016/j.critrevonc.2010.05.003. View